Company Disclosure

Financial Results Overview

Standalone Performance (₹ in Lakh)

Quarter Ended September 30, 2026:

  • Total Income from Operations: ₹12,669
  • Net Profit Before Tax: ₹1,408
  • Net Profit After Tax: ₹1,075
  • Total Comprehensive Income: ₹1,105
  • EPS: ₹1.76

Quarter Ended September 30, 2025 (YoY Comparison):

  • Total Income from Operations: ₹9,081
  • Net Loss Before Tax: ₹(2,093)
  • Net Loss After Tax: ₹(1,564)
  • Total Comprehensive Loss: ₹(1,563)
  • EPS: ₹(2.55)

Half-Year Ended September 30, 2026:

  • Total Income from Operations: ₹26,140
  • Net Profit Before Tax: ₹1,608
  • Net Profit After Tax: ₹1,214
  • Total Comprehensive Income: ₹1,272
  • EPS: ₹1.98

Half-Year Ended September 30, 2025 (YoY Comparison):

  • Total Income from Operations: ₹20,306
  • Net Loss Before Tax: ₹(2,977)
  • Net Loss After Tax: ₹(2,234)
  • Total Comprehensive Loss: ₹(2,231)
  • EPS: ₹(3.65)

Consolidated Performance (₹ in Lakh)

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹18,967
  • Net Profit Before Tax: ₹1,699
  • Net Profit After Tax: ₹1,191
  • Total Comprehensive Income: ₹1,229
  • EPS: ₹1.90

Quarter Ended September 30, 2025 (YoY Comparison):

  • Revenue from Operations: ₹14,113
  • Net Loss Before Tax: ₹(1,917)
  • Net Loss After Tax: ₹(1,401)
  • Total Comprehensive Loss: ₹(1,402)
  • EPS: ₹(2.27)

Half-Year Ended September 30, 2026:

  • Revenue from Operations: ₹38,924
  • Net Profit Before Tax: ₹2,056
  • Net Profit After Tax: ₹1,411
  • Total Comprehensive Income: ₹1,487
  • EPS: ₹2.27

Half-Year Ended September 30, 2025 (YoY Comparison):

  • Revenue from Operations: ₹30,783
  • Net Loss Before Tax: ₹(1,261)
  • Net Loss After Tax: ₹(1,005)
  • Total Comprehensive Loss: ₹(1,008)
  • EPS: ₹(1.62)

Segment-wise Performance (Consolidated)

Vaccines Segment:

  • Q2 FY27 Revenue: ₹12,422 lakh
  • Q2 FY27 Profit Before Tax: ₹1,685 lakh
  • H1 FY27 Revenue: ₹25,889 lakh
  • H1 FY27 Profit Before Tax: ₹2,432 lakh

Formulations Segment:

  • Q2 FY27 Revenue: ₹6,545 lakh
  • Q2 FY27 Profit Before Tax: ₹14 lakh
  • H1 FY27 Revenue: ₹13,035 lakh
  • H1 FY27 Loss Before Tax: ₹(376) lakh

Exceptional Items

During H1 FY27, the Group recognized exceptional income of ₹551 lakh (H1 FY25: ₹1,402 lakh) comprising:

  • ₹Nil from settlement with Apotex Inc., USA (H1 FY25: ₹858 lakh)
  • ₹551 lakh from deferred consideration from sale of domestic pharmaceutical brands of PBPL (H1 FY25: ₹544 lakh)

Balance deferred consideration of ₹468 lakh (September 30, 2025: ₹1,567 lakh) remains as Contract Liability.

Assets and Liabilities Position

Standalone (September 30, 2026)

  • Total Assets: ₹90,906 lakh
  • Total Equity: ₹29,795 lakh
  • Equity Share Capital: ₹613 lakh
  • Non-current Liabilities: ₹29,459 lakh
  • Current Liabilities: ₹31,652 lakh

Consolidated (September 30, 2026)

  • Total Assets: ₹132,482 lakh
  • Total Equity: ₹84,411 lakh
  • Equity Share Capital: ₹613 lakh
  • Non-current Liabilities: ₹9,014 lakh
  • Current Liabilities: ₹39,057 lakh

Cash Flow Summary

Standalone H1 FY27

  • Net Cash from Operating Activities: ₹3,375 lakh
  • Net Cash Used in Investing Activities: ₹(3,154) lakh
  • Net Cash from Financing Activities: ₹450 lakh
  • Net Increase in Cash: ₹671 lakh

Consolidated H1 FY27

  • Net Cash from Operating Activities: ₹2,338 lakh
  • Net Cash Used in Investing Activities: ₹(3,136) lakh
  • Net Cash from Financing Activities: ₹1,007 lakh
  • Net Increase in Cash: ₹209 lakh

Going Concern Disclosure

The Company disclosed going concern uncertainty due to negative retained earnings of ₹205.10 crore as of September 30, 2026 (September 30, 2025: ₹211.40 crore negative). However, management affirms continuation based on:

  • Surplus funds from March 2022 brand sales strengthening working capital
  • New facilities for vaccine manufacturing capacity enhancement
  • Scaling up nutrition and pharmaceutical formulations business
  • Higher long-term vaccine orders from institutional customers

Subsidiaries Included in Consolidation

The consolidated results include:

1. Panacea Biotec Pharma Limited

2. Panacea Biotec (International) S.A.

3. Panacea Biotec Germany GmbH

4. PanEra Biotec Private Limited*

5. Meyten Realtech Private Limited

6. Adveta Power Private Limited*

7. Panacea Biotec Inc

*Entities considered subsidiaries for consolidation as per Ind AS 110

Auditor's Review

Suresh Surana & Associates LLP conducted limited review and concluded nothing has come to their attention that causes them to believe the financial results contain material misstatement.